Table 3 Analysis of primary endpoints (Study B) prior to 4-weeks regular treatment with SFC (50/100 mcg) or FBC (4.5/160 mcg)
SFC (n = 74) | FBC (n= 69) | Statistics SFC-FBC | |||
|---|---|---|---|---|---|
Difference (se) | 95% CI | P value | |||
Slope of decline in FEV 1 (ml/hr) from 2–24 hours post dose | |||||
Adjusted mean (se) | -15.97 (1.91) | -14.15 (1.98) | 1.82 (2.04) | -5.88, 2.24 | 0.375 |
Area under FEV 1 curve (weighted mean, Lxmin) | |||||
Adjusted mean (se) | 0.21 (0.04) | 0.22 (0.04) | -0.01 (0.04) | -0.09, 0.06 | 0.721 |
Mean change from pre-dose FEV 1 (L) at 12 hours post dose | |||||
Adjusted baseline mean (se) | 2.97 (0.04) | 2.96 (0.04) | 0.01 (0.04) | -0.08, 0.09 | 0.892 |
Adjusted mean change (se) | 0.21 (0.04) | 0.20 (0.04) | |||